Pyrazine-2-Carboxylic Acid Hydrazide → 7-[(2,4-Dichloro-3-fluorophenyl)carbonyl]-3-(2-pyrazinyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine

HRID 1889080

반응식

HRID 1889080 반응식
[Cl:1][C:2]1[C:7]([F:8])=[C:6]([Cl:9])[CH:5]=[CH:4][C:3]=1[C:10]([N:12]1[CH2:17][CH2:16][NH:15][C:14](=O)[CH2:13]1)=[O:11].F[B-](F)(F)F.C([O+](CC)CC)C.[N:31]1[CH:36]=[CH:35][N:34]=[CH:33][C:32]=1[C:37]([NH:39][NH2:40])=O>ClCCl>[Cl:1][C:2]1[C:7]([F:8])=[C:6]([Cl:9])[CH:5]=[CH:4][C:3]=1[C:10]([N:12]1[CH2:17][CH2:16][N:15]2[C:37]([C:32]3[CH:33]=[N:34][CH:35]=[CH:36][N:31]=3)=[N:39][N:40]=[C:14]2[CH2:13]1)=[O:11]

참가 물질

5

실험 절차

To a solution of 4-[(2,4-dichloro-3-fluorophenyl)carbonyl]-2-piperazinone (I37) (0.146 g, 0.5 mmol) in Dichloromethane (DCM) (3 mL) was added triethyloxonium tetrafluoroborate (0.100 g, 0.525 mmol). The solution was then stirred, under argon, for 10 minutes before 2-pyrazinecarbohydrazide (commercially available from e.g. TimTec, J& W PharmLab and Akos Consulting, 0.083 g, 0.600 mmol) was added. The solution was then stirred for a further hour before the solvent was concentrated and n-butanol (3.00 mL) was added. The solution was then stirred, under argon and reflux, for 3 hours before being cooled to room temperature. The solvent was then evaporated in vacuo and the remaining residue was purified by flash chromatography (Biotage SP4, 25M cartridge) with a gradient of 0-10% 2M NH3/MeOH in DCM. TLC confirmed product location and the solvent from the combined fractions was evaporated in vacuo. The remaining residue was then further purified by mass-direct automated HPLC, before the solvent was again evaporated in vacuo. The remaining solid was then triturated in ether before being dried in a vac-oven to yield the product in 0.056 g.

후처리

  1. additionwas added
  2. concentrationwas concentrated
  3. additionn-butanol (3.00 mL) was added
  4. stirringThe solution was then stirred, under argon
  5. temperaturereflux, for 3 hours
  6. customThe solvent was then evaporated in vacuo
  7. customthe remaining residue was purified by flash chromatography (Biotage SP4, 25M cartridge) with a gradient of 0-10% 2M NH3/MeOH in DCM
  8. customthe solvent from the combined fractions was evaporated in vacuo
  9. customThe remaining residue was then further purified by mass-direct automated HPLC, before the solvent
  10. customwas again evaporated in vacuo
  11. customThe remaining solid was then triturated in ether
  12. custombefore being dried in a vac-oven
  13. customto yield the product in 0.056 g

출처 및 근거

ORD 기록
ord-3b6d521a11e841ac989f192d4d123ed4
출처 데이터셋
uspto-grants-2013_08
특허 번호
US08501946B2

연결된 노트

불러오는 중…